Circulating tumor cells (CTCs) are tumor cells that have sloughed off the primary tumor and
extravasate into and circulate in the blood. Understanding of the metastatic cascade of CTCs …

Predictive biomarkers aid selection of personalized therapy targeted to molecular alterations
within an individual's tumor. Patients' responses to targeted therapies are commonly …

Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor with early
dissemination and dismal prognosis, accounts for 15–20% of lung cancer cases and∼ …

In most patients with small-cell lung cancer (SCLC)—a metastatic, aggressive disease—the
condition is initially chemosensitive but then relapses with acquired chemoresistance. In a …

Purpose Circulating tumor cells (CTCs) may have utility as surrogate biomarkers and
“virtual” biopsies. We report the clinical significance and molecular characteristics of CTCs …

Circulating tumor cells (CTCs) shed from primary and metastatic cancers are admixed with
blood components and are thus rare, making their isolation and characterization a major …

Purpose Lung cancer is the leading cause of cancer-related death worldwide. Non–small-
cell lung cancer (NSCLC) lacks validated biomarkers to predict treatment response. This …

Abstract The CellSearch® system (CS) enables standardized enrichment and enumeration
of circulating tumor cells (CTCs) that are repeatedly assessable via non-invasive “liquid …

The outcomes of patients with SCLC have not yet been substantially impacted by the
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …

Purpose: Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of
small cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of …